Thrombin and cancer: From molecular basis to therapeutic implications

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 1, 2012, Pages 95-101

  Franchini, Massimo ^a   Mannucci, Piermannuccio ^b  

^a CARLO POMA HOSPITAL   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

anticoagulant; cancer; hemophilia; thrombin

Indexed keywords

THROMBIN;

ANTICOAGULANT THERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CONFERENCE PAPER; HEMOPHILIA; METASTASIS; NEOPLASM; PRIORITY JOURNAL; THROMBOSIS;

EID: 84857000398     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1300955     Document Type: Conference Paper

References (71)

1. De Bouillaud S. Lobliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med: 1823; 1 188 204
2. Trousseau A. Phlegmasia alba dolens. In: Trousseau A, ed. Clinique Medicinale de lHotel-Dieu de Paris. Paris, France: JB Bailliere et fils; 1865;:645-712
3. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res: 2001; 102 6 V187 V194 (Pubitemid 32539209)
4. Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis: 2007; 24 1 29 38 (Pubitemid 46831561)
5. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest: 1991; 87 1 229 236
6. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost: 2007; 5 Suppl 1 246 254 (Pubitemid 46958840)
7. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost: 2004; 30 1 63 69 (Pubitemid 38457301)
8. Hu L, Lee M, Campbell W, Perez-Soler R, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood: 2004; 104 9 2746 2751 (Pubitemid 39434957)
9. Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood: 2000; 95 10 3133 3138 (Pubitemid 30321164)
10. Franchini M, Montagnana M, Favaloro EJ, Lippi G. The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. Semin Thromb Hemost: 2009; 35 7 644 653
11. Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med: 2007; 45 1 2 12 (Pubitemid 46155552)
12. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost: 2006; 32 Suppl 1 61 68
13. Snyder KM, Kessler CM. The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost: 2008; 34 8 734 741
14. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost: 1995; 74 1 282 290
15. OReilly MS. Antiangiogenic antithrombin. Semin Thromb Hemost: 2007; 33 7 660 666
16. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost: 2001; 86 4 1094 1098 (Pubitemid 32975838)
17. Wang J, Morita I, Onodera M, Murota SI. Induction of KDR expression in bovine arterial endothelial cells by thrombin: involvement of nitric oxide. J Cell Physiol: 2002; 190 2 238 250 (Pubitemid 34027826)
18. Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis. Cancer Res: 2006; 66 8 4125 4132
19. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood: 2002; 99 5 1646 1650 (Pubitemid 34533037)
20. Duhamel-Clrin E, Orvain C, Lanza F, Cazenave JP, Klein-Soyer C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vasc Biol: 1997; 17 10 1931 1938 (Pubitemid 28057092)
21. Pinedo HM, Verheul HM, DAmato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet: 1998; 352 9142 1775 1777
22. English D, Garcia JG, Brindley DN. Platelet-released phospholipids link haemostasis and angiogenesis. Cardiovasc Res: 2001; 49 3 588 599 (Pubitemid 32146422)
23. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost: 2007; 33 7 688 694 (Pubitemid 350157013)
24. Mousa SA. Anti-thrombotics in thrombosis and cancer. Future Oncol: 2005; 1 3 395 403
25. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev: 2001; 53 1 93 105 (Pubitemid 32173109)
26. Bobek V, Kovark J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother: 2004; 58 4 213 219 (Pubitemid 38746746)
27. Weitz IC, Liebman HA. The role of oral anticoagulants in tumor biology. Semin Thromb Hemost: 2007; 33 7 695 698 (Pubitemid 350157014)
28. Langer F, Amirkhosravi A, Ingersoll SB., et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost: 2006; 4 5 1056 1062
29. Brüggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. J Cell Mol Med: 2008; 12 6B 2622 2627
30. Franchini M, Lippi G, Montagnana M., et al. Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev: 2009; 35 4 374 377
31. Mannucci PM, Schutgens REG, Santagostino E, Mauser-Bunschoten EPM. How I treat age-related morbidities in elderly persons with hemophilia. Blood: 2009; 114 26 5256 5263
32. Dunn AL. Malignancy in patients with haemophilia: a review of the literature. Haemophilia: 2010; 16 3 427 436
33. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol: 2010; 148 4 522 533
34. Walker IR, Julian JA. Causes of death in Canadians with haemophilia 1980-1995. Association of Hemophilia Clinic Directors of Canada. Haemophilia: 1998; 4 5 714 720 (Pubitemid 28442426)
35. Darby SC, Kan SW, Spooner RJ., et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood: 2007; 110 3 815 825 (Pubitemid 47267416)
36. Tagliaferri A, Rivolta GF, Iorio A., et al. Italian Association of Hemophilia Centers. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia: 2010; 16 3 437 446
37. Plug I, Van Der Bom JG, Peters M., et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost: 2006; 4 3 510 516
38. Miesbach W, Alesci S, Krekeler S, Seifried E. Comorbidities and bleeding pattern in elderly haemophilia A patients. Haemophilia: 2009; 15 4 894 899
39. Sikuler E, Shnaider A, Zilberman D., et al. Hepatitis C virus infection and extrahepatic malignancies. J Clin Gastroenterol: 1997; 24 2 87 89 (Pubitemid 27142929)
40. Miesbach W, Seifried E. Does haemophilia influence cancer-related mortality in HIV-negative patients? Haemophilia: 2011; 17 1 55 60
41. Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost: 2004; 2 8 1263 1265 (Pubitemid 40186119)
42. Falanga A, Piccioli A. Effect of anticoagulant drugs in cancer. Curr Opin Pulm Med: 2005; 11 5 403 407 (Pubitemid 41291083)
43. Piccioli A, Falanga A, Prandoni P. Anticoagulants and cancer survival. Semin Thromb Hemost: 2006; 32 8 810 813 (Pubitemid 44956976)
44. Michaels L. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet: 1964; 2 7364 832 835
45. Zacharski LR, Henderson WG, Rickles FR., et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA: 1981; 245 8 831 835 (Pubitemid 11135890)
46. Chahinian AP, Propert KJ, Ware JH., et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol: 1989; 7 8 993 1002 (Pubitemid 19196521)
47. Maurer LH, Herndon JE II, Hollis DR., et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol: 1997; 15 11 3378 3387 (Pubitemid 27485858)
48. Zacharski LR, Henderson WG, Rickles FR., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer: 1984; 53 10 2046 2052 (Pubitemid 14101772)
49. Levine M, Hirsh J, Gent M., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet: 1994; 343 8902 886 889 (Pubitemid 24113632)
50. Daly L. The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Metastasis: 1991; 9 1 3 11
51. Thornes RD, Daly L, Lynch G., et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J Cancer Res Clin Oncol: 1994; 120 Suppl S32 S34 (Pubitemid 24142552)
52. Smorenburg SM, Vink R, Otten HM, Swaneveld F, Büller HR. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost: 2001; 86 6 1586 1587 (Pubitemid 34007540)
53. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med: 2000; 342 26 1953 1958 (Pubitemid 30419090)
54. Tagalakis V, Tamim H, Blostein M, Collet JP, Hanley JA, Kahn SR. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol: 2007; 8 5 395 402 (Pubitemid 46621759)
55. Akl EA, Kamath G, Kim SY., et al. Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database Syst Rev: 2007; 2 2 CD006466
56. Tagalakis V, Blostein M, Robinson-Cohen C, Kahn SR. The effect of anticoagulants on cancer risk and survival: systematic review. Cancer Treat Rev: 2007; 33 4 358 368 (Pubitemid 46760529)
57. Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol: 2010; 3 3
58. Kakkar AK, Hedges R, Williamson RCN, Kakkar V. Perioperative heparin-therapy inhibits late death from metastatic cancer. Int J Oncol: 1995; 6 4 885 888
59. Lebeau B, Chastang C, Brechot JM., et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Celluleso" Group. Cancer: 1994; 74 1 38 45 (Pubitemid 24187607)
60. Nitti D, Wils J, Sahmoud T., et al. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). Eur J Cancer: 1997; 33 8 1209 1215 (Pubitemid 27359637)
61. Fielding LP, Hittinger R, Grace RH, Fry JS. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet: 1992; 340 8818 502 506
62. Smorenburg SM, Hettiarachchi RJ, Vink R, Büller HR. The effects of unfractionated heparin on survival in patients with malignancya systematic review. Thromb Haemost: 1999; 82 6 1600 1604
63. Altinbas M, Coskun HS, Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost: 2004; 2 8 1266 1271 (Pubitemid 40186120)
64. Kakkar AK, Levine MN, Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol: 2004; 22 10 1944 1948 (Pubitemid 41095187)
65. Klerk CP, Smorenburg SM, Otten HM., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol: 2005; 23 10 2130 2135 (Pubitemid 46218704)
66. Sideras K, Schaefer PL, Okuno SH., et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc: 2006; 81 6 758 767 (Pubitemid 43839491)
67. Akl EA, van Doormaal FF, Barba M., et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev: 2007; 18 3 CD006652
68. Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS. FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer: 2009; 9 355
69. Lee AY, Rickles FR, Julian JA., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol: 2005; 23 10 2123 2129 (Pubitemid 46218703)
70. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost: 2007; 5 4 729 737 (Pubitemid 46563571)
71. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer: 2007; 110 5 1149 1161 (Pubitemid 47312882)